The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

For many of Chi­na’s biotech pi­o­neers, li­cens­ing West­ern drugs to de­vel­op and mar­ket specif­i­cal­ly for Chi­nese pa­tients revved up the coun­try’s in­no­va­tion en­gine af­ter decades of be­ing rel­e­gat­ed to gener­ic and API man­u­fac­tur­ing. Even as new star­tups now piv­ot to boast about in-house dis­cov­ery, part­ner­ships with com­pa­nies out­side of Chi­na re­mained in style, cul­mi­nat­ing in a record num­ber of deals in 2019.

Chris Doko­ma­ji­lar

At Deal­For­ma, Chris Doko­ma­ji­lar has been track­ing the li­cens­ing ter­ri­to­ry as well as where the sell­ers and buy­ers are head­quar­tered. Com­pound that with a break­down of the top ther­a­peu­tic ar­eas and tech­nolo­gies of in­ter­est — in ad­di­tion to M&A and ven­ture ac­tiv­i­ty — for Chi­nese play­ers, and you get a com­pre­hen­sive pic­ture of the boom­ing deal scene.

For a bird’s eye view, since 2008 we’ve seen:

• 682 deals with a Chi­nese com­pa­ny
• $28.2 bil­lion in to­tal deal val­ue
• $3.3 bil­lion in up­front cash & eq­ui­ty
• Plus ad­di­tion­al M&A, as­set pur­chas­es, and in­vest­ments

Zoom in to the do­mes­tic mar­ket on­ly, and you get 518 deals for rights sole­ly in Chi­na, $19.7 bil­lion in to­tal deal val­ue, and $2.9 bil­lion in up­front cash & eq­ui­ty.

Re­mem­ber, all fig­ures — and there are plen­ty here — are based on what com­pa­nies have dis­closed in Eng­lish sources. There are bound to be more deals not cap­tured here, but this is the radar we’re stick­ing to. And fi­nal­ly, there’s no telling what kind of im­pact the cur­rent pan­dem­ic will play on these trends — but they’ve been build­ing for more than a decade now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER